Related Experiment Video
Updated: Jul 3, 2026
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
[Triple-negative breast cancer--towards a new entity]
L Miron1, Andreea Marinca, M Marinca
1Universitatea de Medicină şi Farmacie Gr.T. Popa Iaşi, Facultatea de Medicină, Disciplina de Oncologie.
Summary
Triple-negative breast cancer, identified by immunohistochemistry, is linked to poorer patient prognosis and shorter survival rates. This study highlights the importance of molecular subtyping for understanding breast cancer heterogeneity and treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Context:
- Breast cancer is a heterogeneous disease with diverse clinical and molecular features.
- Gene expression profiling offers new insights into tumor classification and treatment prediction.
- Understanding molecular subtypes is crucial for personalized breast cancer care.
Purpose:
- To determine the prevalence of basal-like (triple-negative) breast tumors.
- To assess the impact of molecular subtyping on treatment response, disease-free survival, and overall survival.
- To correlate specific biological and clinical features with breast cancer molecular subtypes.
Summary:
- This study analyzed 96 breast cancer patients, classifying tumors into molecular subtypes using immunohistochemistry.
- Basal-like tumors constituted 15.62% of the sample and did not correlate with histological type, stage, or differentiation.
- Patients with basal-like tumors exhibited significantly shorter time-to-progression, disease-free survival, and overall survival.
Impact:
- The findings underscore the poor prognosis associated with triple-negative breast cancers.
- Immunohistochemical markers (ER, PR, HER2/neu) are valuable for identifying triple-negative tumors and predicting outcomes.
- This research contributes to a better understanding of breast cancer subtypes and their clinical implications.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...